{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:00:34Z","timestamp":1791568834441,"version":"4.3.4"},"reference-count":88,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:00:00Z","timestamp":1793059200000},"content-version":"am","delay-in-days":360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01EB021155"],"award-info":[{"award-number":["R01EB021155"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32GM140223"],"award-info":[{"award-number":["T32GM140223"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009863","name":"Neuroendocrine Tumor Research Foundation","doi-asserted-by":"publisher","award":["1159892"],"award-info":[{"award-number":["1159892"]}],"id":[{"id":"10.13039\/100009863","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic and Interventional Imaging"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.diii.2025.05.005","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T08:07:29Z","timestamp":1747814849000},"page":"385-393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Molecular imaging of neuroendocrine tumors: Current applications and future trends"],"prefix":"10.1016","volume":"106","author":[{"given":"Ivan E.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3781-0007","authenticated-orcid":false,"given":"Helen A.","family":"SaTsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen F.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2897-4694","authenticated-orcid":false,"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.H.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8471-4988","authenticated-orcid":false,"given":"Benjamin L.","family":"Viglianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diii.2025.05.005_bib0001","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in pPatients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.diii.2025.05.005_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-021-01139-2","article-title":"New directions in imaging neuroendocrine neoplasms","volume":"23","author":"Refardt","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.diii.2025.05.005_bib0003","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.diii.2023.06.007","article-title":"Neuroendocrine liver metastases treated using transarterial radioembolization: identification of prognostic parameters at 68Ga-DOTATATE PET\/CT","volume":"105","author":"Ingenerf","year":"2024","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.diii.2025.05.005_bib0004","series-title":"Clinical Presentations Of Endocrine Diseases. Endocr. Pathol","first-page":"1","author":"Gomez-Hernandez","year":"2017"},{"key":"10.1016\/j.diii.2025.05.005_bib0005","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.2147\/CMAR.S174907","article-title":"Prognosis of patients with neuroendocrine tumor: a SEER database analysis","volume":"10","author":"Man","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.diii.2025.05.005_bib0006","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/ph13020022","article-title":"Radiolabelled peptides for positron emission tomography and endoradiotherapy in oncology","volume":"13","author":"Rangger","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.diii.2025.05.005_bib0007","series-title":"Integration Of Pharmaceutical Discovery And Development: Case Histories","author":"Borchardt","year":"1998"},{"key":"10.1016\/j.diii.2025.05.005_bib0008","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci"},{"key":"10.1016\/j.diii.2025.05.005_bib0009","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/snuc.2002.31022","article-title":"Somatostatin receptor imaging","volume":"32","author":"Kwekkeboom","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0010","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.diii.2025.05.005_bib0011","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2967\/jnumed.118.223016","article-title":"111in-pentetreotide scintigraphy versus 68Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden","volume":"60","author":"Hope","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0012","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s002590100639","article-title":"Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data","volume":"28","author":"Hofmann","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0013","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0020-708X(81)90174-5","article-title":"A new 68Ge\/68Ga radioisotope generator system for production of 68Ga in dilute HCl","volume":"32","author":"Schuhmacher","year":"1981","journal-title":"Int J Appl Radiat Isot"},{"key":"10.1016\/j.diii.2025.05.005_bib0014","article-title":"Advanced Accelerator Applications USA Inc., FDA, CDER","year":"2016","journal-title":"NetSpot Package Insert"},{"key":"10.1016\/j.diii.2025.05.005_bib0015","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s00259-006-0317-x","article-title":"Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?","volume":"34","author":"Antunes","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2025.05.005_bib0016","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2967\/jnumed.119.236091","article-title":"64Cu-DOTATATE PET\/CT for imaging patients with known or suspected somatostatin receptor-positive neuroendocrine tumors: results of the first U.S. prospective, reader-masked clinical trial","volume":"61","author":"Delpassand","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0017","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177 Lu- DOTATATE for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0018","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00259-021-05512-y","article-title":"A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE","volume":"49","author":"Zhu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2025.05.005_bib0019","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.2967\/jnumed.111.088922","article-title":"First clinical evidence that imaging with somatostatin receptor antagonists is feasible","volume":"52","author":"Wild","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0020","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/ph16050674","article-title":"Peptide radioligands in cancer theranostics: agonists and antagonists","volume":"16","author":"Nock","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.diii.2025.05.005_bib0021","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2214\/AJR.18.19881","article-title":"Neuroendocrine tumor diagnosis and management: 68 Ga-DOTATATE PET\/CT","volume":"211","author":"Sanli","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.diii.2025.05.005_bib0022","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/gut.38.1.33","article-title":"Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2","volume":"38","author":"John","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.diii.2025.05.005_bib0023","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine practice guideline\/Society of Nuclear Medicine and Molecular Imaging procedure standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma","volume":"46","author":"Ta\u00efeb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2025.05.005_bib0024","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7150\/thno.87345","article-title":"Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments","volume":"14","author":"Richter","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.diii.2025.05.005_bib0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2967\/jnmt.120.258939","article-title":"68Ga-DOTATATE PET\/CT for neuroblastoma staging: utility for clinical use","volume":"49","author":"Maaz","year":"2021","journal-title":"J Nucl Med Technol"},{"key":"10.1016\/j.diii.2025.05.005_bib0026","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00259-010-1720-x","article-title":"Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine","volume":"38","author":"Kroiss","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2025.05.005_bib0027","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2967\/jnmt.122.264694","article-title":"68Ga-DOTATATE PET in restaging and response to therapy in neuroblastoma: a case series and a mini review","volume":"51","author":"AlSadi","year":"2023","journal-title":"J Nucl Med Technol"},{"key":"10.1016\/j.diii.2025.05.005_bib0028","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s13139-022-00761-7","article-title":"68Ga-DOTATATE avid metastatic vertebral renal cell carcinoma in the setting of von Hippel-Lindau syndrome","volume":"56","author":"Patel","year":"2022","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2025.05.005_bib0029","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/RLU.0000000000003775","article-title":"Solitary contralateral adrenal metastasis of renal cell carcinoma: 68Ga-DOTATATE PET\/CT findings","volume":"47","author":"Filizoglu","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/wjnm.WJNM_38_17","article-title":"Metastatic clear cell renal cell carcinoma demonstrating intense uptake on 68Ga-DOTATATE positron emission tomography: three case reports and a review of the literature","volume":"17","author":"Nadebaum","year":"2018","journal-title":"World J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0031","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.210067","article-title":"Dynamic68Ga-DOTATATE PET\/MRI in the diagnosis and management of intracranial meningiomas","volume":"4","author":"Ivanidze","year":"2022","journal-title":"Radiol Imaging Cancer"},{"key":"10.1016\/j.diii.2025.05.005_bib0032","first-page":"349","article-title":"Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [131I] iodobenzylguanidine","volume":"21","author":"Wieland","year":"1980","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0033","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcmg.2009.09.015","article-title":"Development of mIBG as a cardiac innervation imaging agent","volume":"3","author":"Raffel","year":"2010","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.diii.2025.05.005_bib0034","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1530\/EJE-06-0712","article-title":"The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel\u2013Lindau syndrome","volume":"156","author":"Kaji","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.diii.2025.05.005_bib0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1056\/NEJM198107023050103","article-title":"Scintigraphic localization of pheochromocytoma","volume":"305","author":"Sisson","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0036","first-page":"773","article-title":"Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidine","volume":"25","author":"Kimmig","year":"1984","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0037","first-page":"197","article-title":"Radiopharmaceutical treatment of malignant pheochromocytoma","volume":"25","author":"Sisson","year":"1984","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0038","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/08880018609031220","article-title":"Clinical experiences in the treatment of neuroblastoma with 131I-metaiodobenzylguanidine","volume":"3","author":"Treuner","year":"1986","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.diii.2025.05.005_bib0039","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.semnuclmed.2011.05.003","article-title":"Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology","volume":"41","author":"Vallabhajosula","year":"2011","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0040","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1161\/CIRCIMAGING.110.962126","article-title":"Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models","volume":"4","author":"Yu","year":"2011","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.diii.2025.05.005_bib0041","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae049","article-title":"3-[18F]Fluoro-para-hydroxyphenethylguanidine (3-[18F]pHPG) PET: a novel imaging modality for paraganglioma","volume":"8","author":"Else","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.diii.2025.05.005_bib0042","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fmed.2020.00173","article-title":"MIBG therapy for neuroblastoma: precision achieved with dosimetry, and concern for false responders","volume":"7","author":"Rubio","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0043","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/bc00018a006","article-title":"1-(meta-[211At]Astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation","volume":"3","author":"Vaidyanathan","year":"1992","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.diii.2025.05.005_bib0044","first-page":"241560","article-title":"Preparation and preclinical evaluation of [11C]3Br-pHPG to determine its feasibility as a bromine-76\/77 theranostic agent to target norepinephrine transporter in neuroendocrine tumors","volume":"65","author":"SaTsu","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0969-8051(94)90128-7","article-title":"Preparation and pharmacological characterization of [76Br]-meta-bromobenzylguanidine ([76Br]MBBG)","volume":"21","author":"Loc\u2019h","year":"1994","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.diii.2025.05.005_bib0046","first-page":"44","article-title":"Norepinephrine transporter-targeted cancer theranostics: new horizons","volume":"50","author":"Higuchi","year":"2025","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0047","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clinimag.2020.05.035","article-title":"Ga-68 DOTA-peptides and F-18 FDG PET\/CT in patients with neuroendocrine tumor: a review","volume":"67","author":"Evangelista","year":"2020","journal-title":"Clin Imaging"},{"key":"10.1016\/j.diii.2025.05.005_bib0048","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","article-title":"18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors","volume":"16","author":"Binderup","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.diii.2025.05.005_bib0049","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2967\/jnumed.108.057505","article-title":"Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors","volume":"50","author":"Garin","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0050","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.114.144386","article-title":"High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation","volume":"55","author":"Bahri","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0051","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2217\/14796694.5.1.75","article-title":"Update on nuclear medicine imaging of neuroendocrine tumors","volume":"5","author":"Goldsmith","year":"2009","journal-title":"Futur Oncol"},{"key":"10.1016\/j.diii.2025.05.005_bib0052","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2967\/jnumed.123.265584","article-title":"High tumor uptake on 18F-FDOPA PET\/CT indicates poor prognosis in patients with metastatic midgut neuroendocrine tumors: a study from the Groupe d\u2019Etude des Tumeurs Endocrines and ENDOCAN-RENATEN Network","volume":"64","author":"De Rycke","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0053","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cpet.2013.08.013","article-title":"18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors","volume":"9","author":"Minn","year":"2014","journal-title":"PET Clin"},{"key":"10.1016\/j.diii.2025.05.005_bib0054","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00259-013-2342-x","article-title":"18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type","volume":"40","author":"Balogova","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2025.05.005_bib0055","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2007.15.1126","article-title":"Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography","volume":"26","author":"Koopmans","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.diii.2025.05.005_bib0056","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1210\/jc.2004-1938","article-title":"Whole-body 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography","volume":"90","author":"Orlefors","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diii.2025.05.005_bib0057","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMc0802045","article-title":"Glucagon-like peptide 1-receptor scans to localize occult insulinomas","volume":"359","author":"Wild","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0058","first-page":"2025","article-title":"Promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting","volume":"47","author":"Wild","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0059","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1007\/s00259-018-4101-5","article-title":"Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET\/CT, SPECT\/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study","volume":"45","author":"Antwi","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2025.05.005_bib0060","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-1-0716-2807-2_9","article-title":"Protocol for clinical GLP-1 receptor PET\/CT imaging with [68Ga]Ga-NODAGA-Exendin-4","volume":"2592","author":"Tokg\u00f6z","year":"2023","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.diii.2025.05.005_bib0061","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170435","article-title":"Radioiodinated exendin-4 is superior to the radiometal-labelled glucagon-like peptide-1 receptor probes overcoming their high kidney uptake","volume":"12","author":"L\u00e4ppchen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.diii.2025.05.005_bib0062","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/life13040989","article-title":"Role of exendin-4 functional imaging in diagnosis of insulinoma: a systematic review","volume":"13","author":"Sidrak","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.diii.2025.05.005_bib0063","doi-asserted-by":"crossref","first-page":"E386","DOI":"10.1097\/RLU.0000000000003124","article-title":"Pitfalls in the detection of insulinomas with glucagon-like peptide-1 receptor imaging","volume":"45","author":"Antwi","year":"2020","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0064","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2967\/jnumed.110.085142","article-title":"Glucagon-like peptide-1 versus somatostatin receptor targeting reveals two distinct forms of malignant insulinomas","volume":"52","author":"Wild","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0065","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.diii.2024.04.004","article-title":"The cutting edge: promising oncology radiotracers in clinical development","volume":"105","author":"Oldan","year":"2024","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.diii.2025.05.005_bib0066","first-page":"276","article-title":"Cholecystokinin-B\/gastrin receptor: a novel molecular probe for human small cell lung cancer","volume":"55","author":"Matsumori","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.diii.2025.05.005_bib0067","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s002590050241","article-title":"Targeting of cholecystokinin-B\/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin","volume":"25","author":"Behr","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-015-0158-3","article-title":"Impact of clinically tested NEP\/ACE inhibitors on tumor uptake of [111In-DOTA]MG11: first estimates for clinical translation","volume":"6","author":"Kaloudi","year":"2016","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.diii.2025.05.005_bib0069","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3390\/pharmaceutics12121145","article-title":"One step closer to clinical translation: enhanced tumor targeting of [99mTc]Tc-DB4 and [111In]In-SG4 in mice treated with Entresto","volume":"12","author":"Kanellopoulos","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.diii.2025.05.005_bib0070","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.3390\/cancers13225776","article-title":"Update on preclinical development and clinical translation of cholecystokinin-2 receptor targeting radiopharmaceuticals","volume":"13","author":"von Guggenberg","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.diii.2025.05.005_bib0071","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2967\/jnumed.122.264977","article-title":"Preliminary clinical experience with cholecystokinin-2 receptor PET\/CT using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer","volume":"64","author":"von Guggenberg","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0072","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5603\/EP.2016.0010","article-title":"Medullary thyroid carcinoma: PET\/CT imaging with 68Ga-labelled gastrin and somatostatin analogues","volume":"67","author":"Kunikowska","year":"2016","journal-title":"Endokrynol Pol"},{"key":"10.1016\/j.diii.2025.05.005_bib0073","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.7150\/thno.18754","article-title":"Imaging of chemokine receptor 4 expression in neuroendocrine tumors: a triple tracer comparative approach","volume":"7","author":"Werner","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.diii.2025.05.005_bib0074","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/14737140.2024.2341728","article-title":"Pentixather: paving the way for radioligand therapy in oncohematology","volume":"24","author":"Bauckneht","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.diii.2025.05.005_bib0075","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2967\/jnumed.122.265199","article-title":"Theranostics in hematooncology","volume":"64","author":"Buck","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0076","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2025.05.005_bib0077","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0078","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/ph17070833","article-title":"Automated radiosynthesis of [18F]FluoFAPI and its dosimetry and single acute dose toxicological evaluation","volume":"17","author":"Witek","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.diii.2025.05.005_bib0079","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.diii.2025.05.005_bib0080","first-page":"727","article-title":"Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced-stage solid tumors: a case series of nine patients","volume":"63","author":"Ferdinandus","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0081","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/RLU.0000000000004480","article-title":"Impact of 68 Ga-FAPI-04 PET\/CT on staging and therapeutic management in patients with digestive system tumors","volume":"48","author":"Kosmala","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0082","first-page":"1899","article-title":"[18F]FDG and [68Ga]Ga-FAPI-04 imaging for outcome prediction in patients with high-grade neuroendocrine neoplasms","volume":"65","author":"Michalski","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0083","doi-asserted-by":"crossref","first-page":"976","DOI":"10.2967\/jnumed.113.133744","article-title":"The glucose-dependent insulinotropic polypeptide receptor: a novel target for neuroendocrine tumor imaging","volume":"55","author":"Gourni","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0084","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2337\/db20-1096","article-title":"Drug occupancy assessment at the glucose-dependent insulinotropic polypeptide receptor by positron emission tomography","volume":"70","author":"Eriksson","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.diii.2025.05.005_bib0085","article-title":"Introduction of a fatty acid chain modification to prolong circulatory half-life of a radioligand towards glucose-dependent insulinotropic polypeptide receptor","volume":"128\u2013129","author":"Khalil","year":"2024","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.diii.2025.05.005_bib0086","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2967\/jnumed.121.263177","article-title":"Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: implications for uPAR-targeted therapy","volume":"63","author":"Carlsen","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2025.05.005_bib0087","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.diii.2024.07.003","article-title":"Molecular imaging for non-invasive risk stratification of renal masses","volume":"105","author":"Rowe","year":"2024","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.diii.2025.05.005_bib0088","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.diii.2024.09.006","article-title":"Artificial intelligence in radiation therapy: an emerging revolution that will be driven by generative methodologies","volume":"105","author":"Rowe","year":"2024","journal-title":"Diagn Interv Imaging"}],"container-title":["Diagnostic and Interventional Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211568425001032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211568425001032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:29:48Z","timestamp":1761647388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211568425001032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":88,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2211568425001032"],"URL":"https:\/\/doi.org\/10.1016\/j.diii.2025.05.005","relation":{},"ISSN":["2211-5684"],"issn-type":[{"value":"2211-5684","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular imaging of neuroendocrine tumors: Current applications and future trends","name":"articletitle","label":"Article Title"},{"value":"Diagnostic and Interventional Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diii.2025.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de radiologie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}